10.13 Lung Clearance Index (LCI) in adult patients with cystic fibrosis (CF) in the era of CFTR modulators

<sup>1</sup>Magdalena Mulligan, <sup>2</sup>Louise Collins, <sup>1</sup>Daryl Butler, <sup>2</sup>Brian Casserly, <sup>3</sup>Colum Dunne, <sup>1</sup>Barry Linnane

<sup>1</sup>Paediatric Respiratory Department, University Hospital Limerick (UHL), Ireland; <sup>2</sup>Adult Cystic Fibrosis Department, University Hospital Limerick (UHL), Ireland; <sup>3</sup>Graduate Entry Medical School and Centre for Interventions in Infection, Inflammation & Immunity (4i), University of Limerick, Ireland.

**Introduction.** Lung clearance index (LCI) describes ventilation inhomogeneity<sup>1</sup>. It is typically measured by the multiple breath washout (MBW) test, which has been developed to detect early changes in the peripheral airways<sup>2</sup>. The long term effects of highly-effective CFTR modulators on pulmonary outcomes of patients with cystic fibrosis (CF) remain under investigation. The aim of this pilot study was to assess the efficacy of MBW in the adult CF patients at the University Hospital Limerick.

**Materials and Methods.** LCI measurements were performed using the ExhalyzerD, controlled with Spiroware 3.2.1 software. All spirometry tests were carried out using a handheld EasyOne Air spirometer equated with the Quanjer (GLI) 2012 prediction equation. All MBW tests were completed prior to spirometry testing and the study subjects were clinically stable on assessment day.

**Results.** To date, we collected data from 23 independent assessments (Table1). Twenty-one spirometry assessments resulted in a normal FEV<sub>1</sub> value (>80%). The *mean*±*SD* of LCI value for corresponding assessments was  $7.83\pm1.10$ . Although we observed a nonlinear correlation between LCI and ppFEF<sub>25-75%</sub> (Figure1), additional tests will be required to establish more accurate correlation.

**Conclusion.** The MBW has potential for integration into the standard care of adult CF patients with mild lung disease.

Keywords: multiple breath washout, lung clearance index, cystic fibrosis, CFTR modulator.

Disclosures: The authors declare that they have no conflict of interest.

**Acknowledgements:** The authors wish to acknowledge the contribution of TLC4CF who donated the ExhalyzerD to the Adult Cystic Fibrosis Department at UHL.

Corresponding author: Magdalena Mulligan PhD; Email: magdalena.mulligan@hse.ie

## References

1. Robinson P, Goldman M, Gustafsson P, Inert gas washout: theoretical background and clinical utility in respiratory disease. Respir 2009; 78:339-355.

2. Gustafsson P, Aurora P, Lindblad A, Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. Eur Respir J 2003; 22:972-9.

Parameter	median; [range]
Age [years]	<b>21</b> ; [16 – 27]
Height [cm]	<b>169</b> ; [150 – 189]
Weight [kg]	<b>69.8</b> ; [50.4 – 91.7]
BMI [kg/m <sup>2</sup> ]	<b>24.1</b> ; [19.2 – 28.9]
LCI <sub>2.5</sub> [TO]	<b>7.62</b> ; [6.53 – 10.57]
ppFEV1 [%]	<b>96</b> ; [58 – 113]
ppFEF <sub>25-75%</sub> [%]	<b>84</b> ; [23 – 140]

Table 1. Characteristics and lung function parameters.



Figure 1. LCI vs ppFEF<sub>25-75%</sub> in adults with CF (one test was excluded from this analysis).